CVKD — Cadrenal Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1937993 ·
Last close
$2.01
Market Cap
$6.23M
52W High
$7.27
52W Low
$1.86
ADV30
80,667
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,514,378 | -2,496,540 | 2,862,067 | 2,308,137 | 1,064,952 |
| Dec 2025 | 0 | — | -3,065,106 | -3,038,990 | 4,326,708 | 4,007,789 | 1,587,982 |
| Sep 2025 | 0 | — | -2,733,803 | -2,685,705 | 4,087,622 | 3,860,082 | 1,352,675 |
| Jun 2025 | 0 | — | -3,734,291 | -3,667,287 | 5,978,431 | 5,570,730 | 1,679,518 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,601,666
Investing CF
$-5,104
Financing CF
$6,596,617
CapEx
$-5,104
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-38,960,145
Inventory
—
Receivables
$5,096
ST Investments
—
EBIT TTM
$-13,461,176
Pretax Income TTM
$-13,237,362
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,461,177 | -13,237,362 | 4,326,708 | 1,587,982 | — | -12,601,666 |
| Dec 2024 | 0 | -10,960,619 | -10,651,368 | 10,123,533 | 2,683,958 | — | -7,357,550 |
| Dec 2023 | 0 | -7,632,843 | -8,357,086 | 8,519,250 | 826,875 | — | -3,530,323 |
| Dec 2022 | — | — | — | 778,174 | 6,329,324 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals, Inc. | $6.19M | $1.44 | — |
| ALZN | Alzamend Neuro, Inc. | $6.28M | $1.31 | — |
| ENVB | Enveric Biosciences, Inc. | $6.32M | $1.57 | — |
| PULM | Pulmatrix, Inc. | $6.35M | $1.74 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $5.95M | $2.15 | — |
News headlines (Yahoo Finance, 1h cache)
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
2026-07-21 12:00 · Yahoo
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
2026-07-13 13:00 · Yahoo
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-07-01 00:00 · Yahoo
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
2026-06-24 12:00 · Yahoo
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
2026-06-18 13:00 · Yahoo
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
2026-06-15 12:30 · Yahoo
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
2026-06-03 13:00 · Yahoo
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-19 20:30 · Yahoo
CVKD: Designing Phase 3 Trial for CAD-1005 in HIT
2026-05-08 12:15 · Yahoo
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
2026-05-07 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.